NCT03598595 2026-02-04
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
21 trialsNCT04201457 2026-02-03
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Pediatric Brain Tumor Consortium
Phase 1/2 Active not recruiting
NCT05842174 2026-01-22
TAQE
VA Office of Research and Development
Phase 1/2 Not yet recruiting
NCT05036226 2025-10-06
COAST
Medical University of South Carolina
Phase 1/2 Recruiting
NCT04464759 2025-07-08
LIMIT
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting
NCT06939582 2025-04-29
RIOM
West China Hospital
Phase 1/2 Recruiting
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04214418 2024-12-18
MEKiAUTO
Columbia University
Phase 1/2 Terminated
NCT06328387 2024-03-25
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT03513211 2023-11-22
HITMAN-PC
St Vincent's Hospital, Sydney
Phase 1/2 Completed
NCT00765765 2023-08-09
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT04593758 2023-05-24
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Cornerstone Pharmaceuticals
Phase 1/2 Completed
NCT03754179 2021-04-28
COMBI-R2
Universitair Ziekenhuis Brussel
Phase 1/2 Unknown
NCT03081702 2021-04-02
A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer
University Health Network, Toronto
Phase 1/2 Completed
NCT03400254 2020-04-28
GLACIER
Abramson Cancer Center at Penn Medicine
Phase 1/2 Withdrawn
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT00486603 2019-07-10
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01128296 2019-05-01
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
University of Pittsburgh
Phase 1/2 Completed
NCT01206530 2019-04-18
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT00728845 2017-05-23
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT00809237 2013-12-10
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
National University Hospital, Singapore
Phase 1/2 Unknown